top
Please input keywords
Biocytogen
Innovative technologies drive the R&D of new drugs
Biocytogen(02315.HK) is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMice HiTS Platform).We aspire to accelerate innovation through external partnerships.
Pipeline
To streamline the entire drug development process
We are committed to working with global partners to develop innovative antibody drugs to benefit patients as soon as possible.
テクノロジープラットフォームテクノロジープラットフォームテク
独自のRenMiceベース®プラットフォーム
独自のRenMiceTMプラットフォームに基づいて、我々はGPCR技術プラットフォーム、TCR抗体技術、双抗技術プラットフォームなどを含む抗体薬物発見技術の全プラットフォームシステムを構築し、有効に規模化革新抗体薬物の開発プロセスを加速させる。
Collaborations
Leveraging strengths offering flexibilities pursuing win-win
50therapeutic antibody co-development/out-licensing/transfer agreements
42target-nominated RenMiceTM licensing projects
Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement
Beijing, China, February 19, 2024 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc. The agreement provides Gilead access to Biocytogen’s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development. Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead’s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are thrilled to collaborate with Gilead, a partner renowned for their drug development and commercialization expertise. Our extensive library of RenMice®-derived, fully human antibodies could serve as an important resource for Gilead to accelerate development of multiple novel antibody-based therapeutics to treat a variety of diseases. We are committed to supporting Gilead as well as our other partners in their drug development endeavors to benefit patients.”About Biocytogen’s Fully Human Antibody Library Biocytogen’s antibody library was generated using a series of proprietary RenMice® platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMabTM mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties. Second-generation RenLite® and RenNano® models, which generate common light chain antibodies and heavy-chain-only antibodies, respectively, further facilitate generation of fully human multi-specific antibodies or nanobodies. RenMice have also been engineered to lack specific drug targets; these targeted knockout platforms can generate antibodies with enhanced sequence and epitope diversity. This platform increases the likelihood of discovering novel species cross-reactive antibodies to facilitate downstream in vivo screening and identification of differentiated antibody candidates. A library featuring available antibody sequences along with characterization data is ready for immediate evaluation and partnership opportunities.About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.Biocytogen Contacts Antibody assets and platforms: BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma
BEIJING, China & BOSTON, Massachusetts, USA—(Business Wire)----Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315),  a global biotech company focusing on the discovery of novel antibody therapeutics, today announces that it has entered into an Exclusive Option and License Agreement with Radiance Biopharma Inc. (“Radiance”), a biotechnology company specializing in developing next generation Antibody Drug Conjugates. The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate (BsADC) for therapeutic product development, manufacturing and commercialization for all human indications worldwide. HER2 and TROP2 are two tumor-associated antigens (TAAs) that have been found to be commonly expressed and co-expressed by multiple tumor types, including breast, gastric, colorectal, bladder, pancreatic, and non-small-cell lung cancer. Under the terms of the agreement, upon the option exercised, Biocytogen will be entitled to receive an option fee, licensing fee, development and commercialization milestone payments, as well as single-digit royalties on net sales. In addition, Biocytogen has the right to collect the sharing of sublicensing fee, if any, between Radiance and third party.Dr. Yuelei Shen, President and CEO of Biocytogen, said: “We are excited to collaborate with Radiance, a strong team with extensive experience in drug development, to develop a leading proprietary fully human bispecfic antibody drug conjugate. We are optimistic that the combination of our strength in BsADC discovery and the extensive experience of Radiance’s team will help expedite the commercialization of this dual-targeting BsADC.”Marc Lippman, MD, Chairman of the Board of Radiance said: “We are excited to enter into this Exclusive Option and License Agreement with Biocytogen for a novel human anti- HER2 and Trop2 Bispecific Antibody Drug Conjugate. Preclinical data from in vitro and in vivo assays of this BsADC shows promising high potency of anti-tumor activities in leading tumor indications. We are eager to work with Biocytogen to move the product to the clinic to benefit patients.”About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established an off-the-shelf library of over 400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.About Radiance Biopharma Radiance is focused on developing a pipeline of antibody-based cancer therapeutics including mono and bispecific Antibody Drug Conjugates (ADCs) for the treatment of cancer and to address other unmet medical needs. Marc Lippman, MD, a co-founder and Chairman of the Board of Radiance is a renowned oncologist and former founding board member of Seagen, a leader in the field of ADCs, recently acquired by Pfizer. Based in Boston, Massachusetts, Radiance has a world class, proven leadership team that brings together the best of ADC engineering, clinical, managerial expertise and track record. Radiance is an affiliated company to Alphageneron Pharmaceuticals Inc., a clinical-stage biotechnology company developing unique targeted cell and gene therapies for treating cancer and other unmet medical needs. For more information, please visit www.radiancebiopharma.com .This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. Radiance does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.For Further information on Radiance Biopharma Info@radiancebiopharma.com Tel. 617.621.7143Investor Relations:Trinity Capital Advisors jerry.alain@trinitycapitaladvisers.com Biocytogen Contacts: Antibody assets and platforms: BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn
Manhattan BioSolutions Enters into Evaluation and Potential Licensing Agreement with Biocytogen for Use of Innovative Antibodies in Targeted Therapies
by Mbio2018 | Published January 3, 2024https://manhattanbiosolutions.com/2024/01/03/biocytogen/https://www.issuewire.com/manhattan-biosolutions-enters-into-evaluation-and-potential-licensing-agreement-with-biocytogen-1787056150088970New York City, New York and Beijing, China, January 3, 2024 – Manhattan BioSolutions, Inc. (Manhattan Bio or MABS), an emerging biotech company developing innovative precision biologics, today announced it has entered into an evaluation and potential licensing agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focused on the discovery of novel antibody-based therapeutics. Manhattan Bio gains access to antibodies targeting a promising new tumor antigen that is aberrantly overexpressed in across multiple solid tumor types.The antigen is an ovarian-specific developmental signaling protein. While normally restricted to ovary, testis and adrenal tissues, it becomes highly expressed in ovarian, endometrial and cervical cancers as well as several non-gynecological malignancies including renal, hepatic, colorectal and lung tumors. Notably, the antigen exhibits frequent overexpression particularly across treatment-resistant, aggressive and metastatic cancers. This tumor-specific expression profile makes it an exciting prospect for a precision oncology approach.The agreement provides MABS access to a diverse panel of lead fully-human monoclonal antibody assets generated via Biocytogen’s industry-leading RenMabTM and RenLite® transgenic mouse platforms. Leveraging the platforms’ fully-human antibody repertoires and high immune diversity, Biocytogen has succeeded in developing potential best-in-class antibody candidates recognizing this novel disease protein.Manhattan Bio will evaluate the antibodies in cellular and biochemical assays studies to assess binding affinity, internalization, species cross-reactivity, and other developability parameters to determine suitability for incorporation into antibody-based therapeutic modalities carrying MABS’ proprietary RNA targeting payloads. The most promising candidates may be selected by MABS’ for further development into precision medicines for the treatment of chemoresistant, aggressive or metastatic tumors.“We are extremely pleased to begin this high-potential collaboration on what we believe are groundbreaking antibodies against an emerging cancer target,” said Dr. Boris Shor, CEO of Manhattan Bio. “Combining these unique assets with our next-generation payload technologies offers an exciting opportunity to make a difference for patients battling lethal tumors with limited treatment options available.”“We are excited to provide MABS with our fully human antibodies for the development of novel ADC therapeutics,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Our well-characterized antibodies, demonstrating favorable internalization activity, hold great promise in facilitating the delivery of MABS’ novel RNA nuclease payloads for tumor treatment. This collaboration may expand the applications of our therapeutic antibodies in the field of ADC and make previous small molecule-undruggable targets druggable.”Additional financial details were not disclosed.About Manhattan BioSolutionsManhattan BioSolutions, Inc is a privately held biotechnology company focused on the development of biologic immunotherapies targeting host defense pathways for the treatment of advanced cancers. The company advances two technology platforms for drug discovery: RNA-degrader proteins, and antibody-drug conjugates (ADCs) – through collaborations with leading academic institutions. Manhattan Bio has established partnerships with the National Cancer Institute (NCI), Stony Brook University, The University at Buffalo, Binghamton University, INSERM, Nascent Biotech, EVQLV, and has been awarded grants by the National Institutes of Health (NIH), the National Science Foundation (NSF), the New Jersey Commission on Science, Innovation and Technology (CSIT), the New York State Center For Biotechnology and the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UBCAT). Learn more at manhattanbiosolutions.com and follow Manhattan BioSolutions on LinkedIn or on X (Twitter).About BiocytogenBiocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.Contact for investor inquiries:Jordana Lovett, PhDDirector of Investor Relations(857) 600-1021 ir@manhattanbiosolutions.comBiocytogen ContactsAntibody assets and platforms: BD-Licensing@biocytogen.comMedia: pr@bbctg.com.cn
会社ニュース
BIO-Europe Spring 2024 | Schedule 1-on-1 Meetings with Biocytogen
Biocytogen’s antibody BD and licensing team is pleased to attend and host 1-on-1 meetings at BIO-Europe Spring, taking place March 18-20, 2024 in Barcelona, Spain. Biocytogen’s antibody therapeutics R&D division, RenBiologics, offers antibody sequence licensing/co-development, and RenMice® fully human antibody/TCR discovery platform licensing opportunities.RenBiologics: Our Fully Human Library. Your Pipeline. Our team of antibody discovery experts has established a library of over 400,000 fully human antibody sequences against hundreds of targets. This antibody library is available for partners to develop different therapeutic modalities to treat cancer, autoimmune diseases, metabolic diseases, neurological diseases, and other diseases.Antibodies and antibody-based assets available for partnership: 40+ PCC-stage antibody assets: B7-H3, Siglec-15, TNFR2, MUC16, NKG2D, ROR1, TIGIT, IL-2RA, AMHR2, CD73, CD40 (antagonist), and more;70+ TAA antibodies for plug-and-play: MUC1, 5T4 (TPBG), PTK7, FOLR1, CEACAM6, PSMA, B7-H3, CDH3, DLL3, SEZ6, HER3, HLA-G, LIV-1, ROR1, MUC16, and more;10+ fully human bsAb: RenLite® derived 4-1BB x CD40 bsAb for oncology, OX40 x OX40 (biparatopic) bsAb for autoimmunity, and more;20+ bsADC: RenLite derived PTK7 x TROP2 bsADC, HER3 x MET bsADC, PTK7 x EGFR bsADC, PTK7 x B7-H3 bsADC, and more;10+ TCR-mimic antibodies: RenTCR-mimicTM derived antibodies against WT1、KRAS、P53、AFP、GP100、NY-ESO-1 and other intracellular targets;50+ nanobodies and Nano 100 Project: RenNano® derived HCAbs/nanobodies against TFR1 (blood-brain-barrier crossing), 4-1BB, OX40, BCMA, and more;60+ fully human GPCR mAb/bsAb programs: CCR8, GPRC5D, LGR5, CCR2, and more.5 clinical-stage assets available for partnership: YH008, a PD-1×CD40 bsAb, which received both FDA and China NMPA IND clearance, is being developed in partnership with Chipscreen NewWay;YH003, a CD40 agonistic mAb in phase II MRCTs for unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC) and phase II in China for unresectable/metastatic mucosal melanoma;YH001, a CTLA-4 mAb in an ongoing phase I clinical trial for the treatment of sarcoma, developed in partnership with TRACON;YH002, an OX40 mAb in phase I clinical trials in Australia and China; YH002 and multiple other clinical-stage antibodies are in clinical trials in partnership with Syncromune for the development of intratumoral immunotherapy;YH004, a 4-1BB mAb in phase I clinical trials in Australia and China.Biocytogen’s antibodies are available for evaluation and out-licensing to pharmaceutical and biotechnology companies. In addition, Biocytogen offers licensing and flexible partnering models for its RenMice fully human antibody/TCR discovery platforms.Biocytogen’s therapeutic antibodies and RenMice discovery platforms have received recognition from biopharmaceutical and biotech companies around the world. As of Dec. 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen will continue to actively seek partnerships to accelerate the development of novel therapies for the benefits of human health worldwide.Contact BD-Licensing@biocytogen.com to set up 1-on-1 meetings and discuss licensing and co-development opportunities!
2024.03.14
Join Us at AACR 2024
Biocytogen is excited to be attending the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. Come visit us at Booth 939 from April 7th - April 10th, and at our 20 posters listed below to learn about some of our groundbreaking advancements, including: RenBiologics: Explore how our new antibody discovery division harnesses the power of our cutting-edge RenMice® platforms to create a library of fully human antibodies and antibody-based bsAb and bsADC assets ready for co-development/out-licensing.BioMice: Learn about our world-class genetically modified mouse and cell models and custom-tailored in vivo/in vitro pharmacology services.Biocytogen’s Poster Presentations ADD TO YOUR ITINERARY Set Up Meetings & Secure Your Swag Bag! We’re excited to connect with you at our posters and booth for 1:1 meetings. Use the meeting link below to reserve a time to engage with our experts. Secure your Biocytogen swag bag online NOW to guarantee your collection of carefully selected items showcasing our sub-brands! Stop by our booth to pick up your essential AACR goodies.Book a Meeting With Us! Secure your Biocytogen swag bag! Some Biocytogen’s RenBiologics collaborators are also going to present at AACR2024:Syncromune’s Oral Presentation: Title: Systemic responses to SYNC-T therapy: in situ personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC)Presenter: Charles J. Link, M.D.Date: April 7, 2024Time: 3:00 – 5:00pm PTSession Title: Cancer Vaccines: Ready for Prime Time?Location: San Diego Convention Center, San Diego, CaliforniaSource: GlobeNewswire | Syncromune® Inc. to Present Initial Clinical Data from SYNC-T™ SV-102 Phase 1 as a Late-Breaker at the American Association for Cancer Research Annual Meeting 2024 CtM Bio’s Poster Presentation Title: A novel tri-specific T cell engager targeting the intracellular oncoprotein WT1Poster Number: 6705Date & Time: Apr 10, 9:00 AM – 12:30 PMPoster Board Number: 3
2024.03.12
Discuss our TAA antibody library and bispecific ADCs at World ADC London 2024!
Biocytogen is excited to attend and deliver oral and poster presentations at the upcoming 14th World ADC London conference, held on March 13th-14th, 2024!Dr. Yi (Benny) Yang, Chief Scientific Officer of Biocytogen, will give an oral presentation entitled “RenBiologics is at the forefront of advancing bispecific ADCs and nanobody ADCs” in the Discovery Stream session on March 13th. In the session, Dr. Yang willIntroduce Biocytogen’s state-of-the-art in vivo antibody discovery engines, featuring RenMabTM, RenLite®, and RenNano® mice, alongside a unique collection of 400k+ fully-human antibody binders validated for about 1000 human targets.Showcase Biocytogen’s innovative plug-and-play strategy for developing novel bispecific ADC programs.In addition, Biocytogen’s antibody Business Development & Licensing team will present 2 posters, introducing our bispecific ADC asset BCG033 (PTK7 x TROP2 bsADC) and our tumor-associated antigen (TAA) antibody library, consisting of antibodies against approximately 200 targets with a proprietary linker/payload for ADC plug-and-play.A Novel PTK7 x TROP2 bispecific ADC, BCG033, demonstrates potent efficacy against TNBC and other tumor xenograftsThe TAA antibody library from RenBiologics: advancing innovation in the field of antibody-drug-conjugates (ADCs)We look forward to discussing licensing and co-development opportunities with you! Contact us at BD-Licensing@biocytogen.com to schedule a meeting with us.About the speakerDr. Yi (Benny) Yang,Chief Scientific Officer of BiocytogenDr. Yang graduated from Fudan University with a Master’s degree in Microbiology. He received his Ph.D. degree in Immunology from University of Connecticut Health Center (UCHC) and completed his postdoctoral training at New York University School of Medicine in Dr. Dan Littman’s research group. Then Dr. Yang was recruited to the Medical University of South Carolina (MUSC) as a tenure-track Assistant Professor at the Department of Microbiology and Immunology. In 2016, he joined Biocytogen and has been leading the antibody drug discovery.About Biocytogen:Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets. As of Dec.31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.Biocytogen’s ContactsAntibody assets and platforms: BD-Licensing@biocytogen.comMedia: pr@bbctg.com.cn
2024.03.11